Tuesday, June 3, 2014 (HealthDay News)-Mouse researchers have identified drugs that they believe are promising prophylactic treatments. Alzheimer’s disease..
In this study, researchers said the compound reduced levels of amyloid beta, a protein associated with this degenerative brain disease, by about half.
years ago Alzheimer’s disease As it develops, amyloid beta begins to accumulate and aggregates in the brain. Scientists believe that helping the brain get rid of this protein in late middle age may prevent the disease.
prevention Alzheimer’s disease After the brain develops and is damaged, it may be more feasible than stopping it, according to researchers at the NYU Langone Medical Center.
“It’s important to prevent the disease from progressing this far,” said Dr. Martin Sadowski, a research leader and associate professor of neurology, psychiatry, biochemistry and molecular pharmacology. It was.
Treatment based on this compound, known as 2-PMAP, may be blocked Alzheimer’s disease, The researcher said. They found that the compounds easily penetrated the brain, specifically targeting amyloid proteins and reducing the risk of certain side effects. Since it is non-toxic to mice, they believe it is likely safe enough to be ingested regularly by people over a long period of time.
“What we want Alzheimer’s disease Prophylactics are drugs that moderately lower amyloid beta and are safe for long-term use, “Sadowsky said in a New York University news release.
“Statins Drug Its low cholesterol It seemed to have those characteristics and had a great influence on prevention. Coronary artery disease.. That’s essentially what many of us are imagining about the future of Alzheimer’s disease, “he added.
However, the results obtained in animal experiments are not always reproduced in humans.
In conducting the survey, it was published online on June 3rd. Annual Neurology Report, Researchers screened a collection of compounds and found that 2-PMAP dramatically reduced the production of amyloid precursor protein (the “maternal protein” of amyloid beta). In the test cell, this reduced amyloid beta levels by more than 50%.
The mice involved in the study were designed to carry the same genetic mutations as people with hereditary morphology. Alzheimer’s disease.. After 5 days of treatment with 2-PMAP, levels of amyloid precursor protein and amyloid beta in the mouse brain were dramatically reduced.
According to a news release, treatment for more than 4 months seemed to prevent the mental deficiencies commonly seen in these mice as they grew older.
Researchers said they are currently working on ways to make 2-PMAP more effective.
Alzheimer’s disease is currently the most common form dementiaAffects more than 5 million Americans. If no effective preventative treatment is developed, the prevalence of the disease is expected to triple by 2050.
-Mary Elizabeth Dallas
Copyright © 2014 Health Day. all rights reserved.
Source: NYU Langone Medical Center, News Release, June 3, 2014
Anti-Alzheimer’s disease drugs are promising in mouse studies
Source link Anti-Alzheimer’s disease drugs are promising in mouse studies